Gilead Sciences Inc. (GILD)
Gilead Sciences' Best Days May Be Ahead - Here's Why
Despite a sharp decline in sales of COVID-19 blockbuster Veklury, Gilead Sciences once again beat consensus revenue and EPS forecasts. The drugs whose performance impressed me greatly in Q1 2025 and which played a key role in maintaining Gilead's EBIT margin above 38% are Biktarvy, Livdelzi, and Yescarta. Meanwhile, the sales dynamics of its oncology franchise left me with mixed feelings, including due to the increasing pressure from more effective CAR T-cell therapies, bispecific antibodies, and ADCs.
GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer
Gileads Trodelvy shows significant improvement in PFS in phase III ASCENT-03 trial for first-line metastatic TNBC, reinforcing potential as backbone therapy.
Gilead Sciences, Inc. (GILD) RBC Capital Markets Global Healthcare Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD ) RBC Capital Markets Global Healthcare Conference May 21, 2025 11:30 AM ET Company Participants Cindy Perettie - Executive Vice President of Kite Conference Call Participants Brian Abrahams - RBC Capital Markets Brian Abrahams Represented by their Executive Vice President of Kite, Cindy Perettie, who is in charge of running their CAR-T franchise. So Cindy, thanks so much for joining us.
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should You Buy, Sell or Hold GILD Stock Post Q1 Earnings Miss?
GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the oncology business is under pressure.
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors
Gilead Sciences has reached a $202 million settlement to resolve a civil fraud lawsuit accusing the company of paying kickbacks to doctors who agreed to prescribe its HIV drugs, the U.S. attorney's office in Manhattan said on Tuesday.
Gilead Sciences agrees to pay $202 million to settle claims of kickbacks to doctors for HIV drug prescriptions
Gilead Sciences agrees to pay $202 million to settle claims of kickbacks to doctors for HIV drug prescriptions
GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline
Gilead Sciences' Q1 earnings and sales miss estimates on lower oncology drug sales. The stock is trading down.
Gilead Sciences, Inc. (GILD) Q1 2025 Earnings Call Transcript
Gilead Sciences, Inc. (NASDAQ:GILD ) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ET Company Participants Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial Officer Dietmar Berger - Chief Medical Officer Andrew Dickinson - CFO Cindy Perettie - EVP, Kite Conference Call Participants Michael Yee - Jefferies Carter Gould - Cantor Fitzgerald James Shin - Deutsche Bank Salveen Richter - Goldman Sachs Tyler Van Buren - TD Cowen Daina Graybosch - Leerink Partners Geoff Meacham - Citigroup Chris Schott - JPMorgan Terrence Flynn - Morgan Stanley Tim Anderson - Bank of America Evan Seigerman - BMO Matthew Biegler - Oppenheimer Courtney Breen - Bernstein Brian Abrahams - RBC Capital Markets Mohit Bansal - Wells Fargo Alexandria Hammond - Wolfe Simon Baker - Redburn Atlantic Operator Good afternoon, everyone, and welcome to Gilead's First Quarter 2025 Earnings Conference Call. My name is Rebecca, and I'll be today's host.
Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
